Top > Search of International Patents > CANCER DIAGNOSIS KIT AND CANCER DIAGNOSIS METHOD

CANCER DIAGNOSIS KIT AND CANCER DIAGNOSIS METHOD

Foreign code F100002328
Posted date Dec 14, 2010
Country WIPO
International application number 2008JP063002
International publication number WO 2009034779
Date of international filing Jul 18, 2008
Date of international publication Mar 19, 2009
Priority data
  • P2007-236048 (Sep 12, 2007) JP
Title CANCER DIAGNOSIS KIT AND CANCER DIAGNOSIS METHOD
Abstract Disclosed are a kit and a method for diagnosing cancer, each of which utilizes a polynucleotide comprising the nucleotide sequence depicted in SEQ ID NO: 1 or 3 or a partial sequence thereof, a polypeptide comprising the amino acid sequence depicted in SEQ ID NO: 2 or 4 or a partial sequence thereof, or an antibody capable of binding specifically to a polypeptide comprising the amino acid sequence depicted in SEQ ID NO: 2 or 4 or a partial sequence thereof. It becomes possible to find a CT antigen useful for the detection, diagnosis or treatment of cancer occurring in a digestive organ, and to develop a novel cancer diagnosis technique utilizing the CT antigen.
Outline of related art and contending technology BACKGROUND ART
Cancer an effective inspection techniques, diagnostic methods and treatment method for establishing, and the high frequency of cancer target expressed stronger in a cancer antigen and the antigen can be found necessary. However, gastrointestinal cancer, in particular gastric cancer, colon cancer includes, inspection, few cancer antigens useful in the diagnostic or therapeutic. Therefore, the inspection of gastrointestinal cancer, a cancer antigen useful in the diagnostic or therapeutic is extremely important to develop.
Human cancer examination, diagnostic or treatment, from the viewpoint of side effects, is expressed in a variety of cancers, restricted to testis in normal tissues cancer, testis antigen (Cancer-Testis antigen, hereinafter 'CT antigen' hereinafter) is believed to be the most useful. To date, identified CT antigen of about 40, have been reported. However, all of these CT antigen to a cancer patient not have strong immunogenicity but, for cancer diagnosis, inspection marker, promising CT antigen or for the treatment of cancer is limited.
Reported current representative CT antigens include, (see non-patent document 1) MAGE, SSX (see non-patent document 2), NY-ESO-1 (see non-patent document 3) and the like. MAGE and NY-ESO-1 Western and about the clinical application, had the advantages of the present invention is obtained (for example, NY-ESO-1 and clinical application of non-patent document 4 for reference). In this way, the treatment of cancer is currently the most promising application to those NY-ESO-1 is considered.
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, Knuth A, Boon T.A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
Gure AO, Tureci O, Sahin U, Tsang S, Scanlan MJ, Jager E, Knuth A, Pfreundschuh M, Old LJ, Chen YT. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int. J. Cancer 72: 965-971, 1997.
Chen YT, Scanlan, MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94: 1914-1918, 1997.
Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. USA 97: 12198-12203, 2000.
Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I,Karbach J, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187:1349-1354, 1998.
Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth AA, Ritter G, Chen YT, Stockert E, Tsushima T, Kumon H, Old LJ, Nakayama E. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. 61: 4671-4674, 2001.
Nakada T, Noguchi Y, Sato S, Ono T, Saika T, Kurashige T, Gnjatic S, Ritter G, Chen YT, Stockert E, Nasu Y, Tsushima T, Kumon H, Old LJ, Nakayama E. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immunity 3: 10, 2003.
Sugita Y, Wada S, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, Scanlan MJ, Ono T, Sakita I, Yasui M, Miyoshi Y, Tamaki Y, Matsuura N, Noguchi S, Old LJ, Nakayama E, Monden M. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.Cancer Res. 64: 2199-2204, 2004.
Fujita S, Wada H, Jungbluth AA. Sato S, Nakata T, Noguchi Y, Doki Y, Yasui M, Sugita Y, Yasuda T, Yano M, Ono T, Chen YT, Higashiyama M, Gnjatic S, Old LJ, Nakayama E, Monden M. NY-ESO-1 expression and immunogenicity in esophageal cancer.Clin. Cancer Res. 10: 6551-6558, 2004.
Nakamura, S, Nouso K, Noguchi Y, Higashi T, Ono T, Jungbluth AA, Chen YT, Old LJ, Nakayama E, Shiratori Y. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 21: 1281-1285, 2006.
Scope of claims (In Japanese)請求の範囲 [1]
 配列番号1もしくは3に示される塩基配列またはその部分配列を含むポリヌクレオチドを備えていることを特徴とする癌を診断するためのキット。

[2]
 配列番号2もしくは4に示されるアミノ酸配列またはその部分配列からなるポリペプチドを備えることを特徴とする癌を診断するためのキット。

[3]
 配列番号2もしくは4に示されるアミノ酸配列またはその部分配列からなるポリペプチドに特異的に結合する抗体を備えていることを特徴とする癌を診断するためのキット。

[4]
 上皮系腫瘍または皮膚癌の診断に用いられることを特徴とする請求の範囲1~3のいずれか1項に記載のキット。

[5]
 胃癌、大腸癌、乳癌、頭頸部癌、肺癌、腎癌、前立腺癌および悪性黒色腫から選択される少なくとも1種の診断に用いられることを特徴とする請求の範囲1~3のいずれか1項に記載のキット。

[6]
 配列番号1もしくは3に示される塩基配列またはその部分配列を含むポリヌクレオチドが被験体由来の試料中に存在するレベルを測定するポリヌクレオチド測定工程を包含することを特徴とする癌診断方法。

[7]
 配列番号2もしくは4に示されるアミノ酸配列またはその部分配列からなるポリペプチドが被験体由来の試料中に存在するレベルを測定するポリペプチド測定工程を包含することを特徴とする癌診断方法。

[8]
 被験体由来の試料において、配列番号2もしくは4に示されるアミノ酸配列またはその部分配列からなるポリペプチドに特異的に結合する抗体のレベルを測定する抗体測定工程を包含することを特徴とする癌診断方法。

[9]
 上皮系腫瘍または皮膚癌の診断に用いられることを特徴とする請求の範囲6~8のいずれか1項に記載の癌診断方法。

[10]
 胃癌、大腸癌、乳癌、頭頸部癌、肺癌、腎癌、前立腺癌および悪性黒色腫から選択される少なくとも1種の診断に用いられることを特徴とする請求の範囲6~8のいずれか1項に記載の癌診断方法。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
  • Inventor
  • ONO, Toshiro
  • NAKAYAMA, Eiichi
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MT NL NO PL PT RO SE SI SK TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close